MCK raises guidance on Q1 strength and Precision Medicine acquisition
Strong Q1 results drove higher EPS and AOI guidance for the oncology and biopharma services focus, alongside the Precision Medicine Group acquisition and continued investments. Medsurg IPO is targeted for 2027.Based on…